Company intelligence / Profile preview

Melza M.

Tokyo, Japan

Ownership: Private
Development stage: Other

Overview

Melza M. is a Japanese biotechnology company focused on the discovery and development of novel small molecule therapeutics for metabolic diseases. The company's primary research focus is on the melanin-concentrating hormone receptor 1 (MCHR1), a key regulator of energy homeostasis and food intake. Melza M. aims to develop potent and selective MCHR1 antagonists as potential treatments for obesity and related metabolic conditions. The company's lead programs are currently in the pre-clinical stage of development.

Therapeutic areas: EndocrinologyMetabolic Disorders
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Melza M..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Melza M..

Explore the full profile